Yashoda Super Specialty Kaushambi
The Subject Expert Committee of Drugs Controller General of India (DCGI) on Wednesday recommended Serum Institute’s indigenously developed quadrivalent human papillomavirus (qHPV) vaccine for cervical cancer patients.
“An expert panel of India’s central drug authority on Wednesday recommended granting of market authorisation to Serum Institute of India (SII) indigenously-developed India’s first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer”, said a source.
The vaccine has been recommended for cervical cancer patients those above 9 years to 26 years of age for both male and female.According to the source, an application has also been sent to the National Technical Advisory Group on Immunisation (NTAGI).
The NTAGI may take the final decision on the HPV vaccine in the next meeting scheduled to be held on June 29.
In a major advancement for the surgical landscape in India, Apollo Spectra Hospital has unveiled…
In an uncommon measure, doctors at a city hospital pulled off a 55-year patient with…
Rabies remains one of the most dangerous yet misunderstood viral diseases in the world. Despite…
Health experts have urged the public to clearly understand the difference between asthma-related breathing problems…
A three-day “Revision Arthroplasty Conference” (RAC 2025) which commenced on Friday in the national capital…
Under the Yellow Ribbon Campaign conceptualized in 1998 by Dr S K Sarin with the…